Alizyme to receive $3 million milestone from Takeda

Takeda Pharmaceutical Company Ltd has decided to start a Phase 3 study in Japan of a new gastrointestinal lipase inhibitor for obesity, cetilistat, which will trigger a $3 million payment to the compound’s developer, Alizyme Plc.